Quick Answer
Perspective Therapeutics, Inc. reported Cash and Equivalents of $30.63 million for fiscal year 2025.
Perspective Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $30.63M | -50.3% |
| 2024 | $61.58M | +566.6% |
| 2023 | $9.24M | -56.0% |
| 2022 | $20.99M | -62.4% |
| 2022 | $55.89M | -12.4% |
| 2021 | $63.83M | +2568.4% |
| 2020 | $2.39M | -55.1% |
| 2019 | $5.33M | +104.8% |
| 2018 | $2.60M | -56.2% |
| 2017 | $5.93M | -41.5% |
| 2016 | $10.14M | +94.0% |
| 2015 | $5.23M | -31.9% |
| 2014 | $7.68M | +164.8% |
| 2013 | $2.90M | +8.5% |
| 2012 | $2.67M | +26.5% |
| 2011 | $2.11M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $26.76M | -88.2% | -7.2% |
| June 30, 2025 | $28.85M | -88.6% | -35.0% |
| March 31, 2025 | $44.41M | -68.8% | -27.9% |
| December 31, 2024 | $61.58M | +566.6% | -72.8% |
| September 30, 2024 | $226.44M | +1159.2% | -10.1% |
| June 30, 2024 | $252.00M | +789.9% | +77.3% |
| March 31, 2024 | $142.12M | +289.9% | +1438.4% |
| December 31, 2023 | $9.24M | -56.0% | -48.6% |
- Perspective Therapeutics, Inc. showed a decrease of -50.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Perspective Therapeutics, Inc.’s cash and equivalents has grown by 1350.1% (from $2.11 million to $30.63 million).
- The most recent figure is from Perspective Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: